Compositions and methods for treating amyotrophic lateral sclerosis in responders
AssigneeKnopp Biosciences LLC
InventorsMichael E. Bozik, Thomas Petzinger, Jr., James L. Mather, Donald Archibald
Life of this patent
Estimating the term…
Abstract
A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof comprising administering to said subject an effective amount of (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole or pharmaceutically acceptable salt thereof, wherein said subject is a treatment responder. In certain embodiments, said subject is a subject with definite amyotrophic lateral sclerosis, a subject with amyotrophic lateral sclerosis symptom onset duration of less than about 18 months, a subject with a high level of serum creatinine, a subject with concomitant riluzole administration and combinations thereof.
Claims22
A method of treating definite amyotrophic lateral sclerosis in a subject in need thereof comprising:
- administering to the subject a therapeutically effective amount of (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole or a pharmaceutically acceptable salt thereof, wherein the subject has an amyotrophic lateral sclerosis symptom onset duration of less than about 18 months.
A method of treating El Escorial definite amyotrophic lateral sclerosis in a subject in need thereof comprising orally administering to the subject about 150 milligrams to about 300 milligrams of (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole or a pharmaceutically acceptable salt thereof twice daily, wherein the subject has an amyotrophic lateral sclerosis symptom onset duration of less than about 18 months.
Dependencies are inferred from the claim text.